Hero image: Jahra Tasfia Reza / Pexels
Vancomycin-soaked grafts and early ACL graft resorption risk
An emerging body of clinical observations suggests that vancomycin-soaked quadriceps tendon grafts used in anterior cruciate ligament reconstruction may be associated with early graft resorption, prompting a re-examination of intraoperative antibiotic protocols. While the mechanism remains under study, surgeons and patients now face a more complex calculus when weighing infection prevention against graft integrity.
Reports from multiple orthopedic and medical news outlets have converged on a single, unsettling observation: the use of vancomycin-soaked grafts in anterior cruciate ligament reconstruction (ACLR) may be linked to early graft resorption. This synthesis examines the claims, the supporting and conflicting evidence, and the clinical implications of this finding. It also identifies where the literature agrees, where it diverges, and how misinformation about vancomycin’s role in ACLR has spread from anecdotal reports to broader adoption without robust long-term data.
Background: The rise of vancomycin-sooked grafts in ACL reconstruction
Vancomycin-soaked grafts have gained popularity in ACLR over the past decade as a strategy to reduce postoperative infection risk, particularly in high-risk patients or in settings where infection control is a priority. The practice emerged from observational reports and small series suggesting that local antibiotic delivery via graft soaking could lower the incidence of surgical site infections without increasing systemic toxicity. The rationale was straightforward: deliver a high concentration of antibiotic directly to the graft-bone interface, where bacterial colonization is most likely to occur.
However, the widespread adoption of vancomycin-soaked grafts occurred largely outside the framework of randomized controlled trials. Instead, it was driven by surgeon preference, institutional protocols, and early observational data suggesting benefit. As a result, the practice became embedded in surgical workflows before long-term outcomes—including graft integrity and functional recovery—were systematically evaluated.
What Medical Dialogues reported: The vancomycin-soaked graft resorption link
According to Medical Dialogues, a recent study observed an association between vancomycin-soaked quadriceps tendon grafts and early graft resorption in ACLR. The report described a series of cases in which patients who received vancomycin-soaked grafts experienced accelerated graft thinning or loss of volume within the first six months after surgery, a timeline that typically precedes full biological incorporation. The observation was described as unexpected and prompted further review of institutional data, with the authors calling for prospective studies to validate the finding and explore mechanisms.
Medical Dialogues emphasized that the resorption was not uniformly severe but occurred with sufficient frequency to raise concern among surgeons reviewing the data. The report did not quantify the incidence across a broader population, nor did it identify specific patient subgroups at highest risk. Nonetheless, it framed the observation as a potential signal that warrants immediate attention, particularly given the growing use of vancomycin-soaked grafts in high-volume centers.
Where the evidence converges and diverges across orthopedic literature
Convergence: Infection prevention vs. graft integrity
Across multiple reports and institutional reviews, there is broad agreement that vancomycin-soaked grafts reduce the risk of postoperative infection in ACLR. This benefit has been consistently observed in retrospective series and registry analyses, particularly in patients with risk factors such as diabetes, obesity, or prior knee surgery. The rationale for local antibiotic delivery is supported by pharmacokinetic studies showing high local concentrations with minimal systemic exposure.
However, this convergence on infection prevention sharply contrasts with emerging reports on graft integrity. While the infection benefit is well-documented, the potential harm to graft structure—specifically early resorption—has only recently been described and remains sparsely reported. The divergence lies not in whether vancomycin reduces infection risk, but in whether its use compromises graft biology in ways that outweigh the infection benefit.
Divergence: Study design, patient populations, and follow-up
Much of the existing literature on vancomycin-soaked grafts consists of retrospective cohort studies, case series, and institutional audits. These designs are prone to selection bias, confounding, and incomplete follow-up, making it difficult to draw firm conclusions about graft resorption. Some reports describe no adverse effects on graft healing, while others note isolated cases of early thinning or resorption, particularly in quadriceps tendon grafts.
The lack of standardized imaging protocols and variable definitions of “resorption” further complicate comparisons across studies. Some authors define resorption as a measurable loss of graft volume on MRI, while others rely on clinical or radiographic signs of graft attenuation. This heterogeneity in outcome assessment limits the ability to synthesize findings across studies and underscores the need for prospective, standardized evaluations.
The core claim: Does vancomycin increase early graft resorption risk?
The central claim under scrutiny is whether vancomycin-soaked grafts are associated with early graft resorption in ACLR. Based on currently available reports, the answer is uncertain but concerning enough to warrant caution. Medical Dialogues described a series in which this association was observed, but the report did not establish causality or quantify risk. Other published accounts similarly describe isolated cases or institutional experiences rather than definitive evidence.
At present, there is no high-quality, peer-reviewed study demonstrating a causal link between vancomycin soaking and graft resorption. However, the convergence of anecdotal reports, institutional audits, and early imaging findings suggests that this is a plausible risk that has not been adequately ruled out. The absence of definitive evidence does not equate to evidence of absence; rather, it reflects a gap in research rather than proof of safety.
Mechanisms at play: How vancomycin may affect tendon-to-bone healing
Potential cytotoxic effects on graft biology
Vancomycin, a glycopeptide antibiotic, is known to have dose-dependent cytotoxic effects on mammalian cells, including fibroblasts and osteoblasts, which are critical for tendon-to-bone healing. In vitro studies have shown that high concentrations of vancomycin can impair cell viability, reduce collagen synthesis, and disrupt extracellular matrix organization. These effects may be exacerbated in avascular grafts such as the quadriceps tendon, where biological incorporation depends on cellular migration and proliferation from surrounding tissues.
Some authors hypothesize that the soaking process delivers a bolus of vancomycin directly into the graft substance, exposing tenocytes and progenitor cells to concentrations far higher than those achieved with systemic administration. Over time, this exposure may impair the early phases of graft remodeling, leading to reduced cellularity, disorganized collagen deposition, and ultimately, structural weakening and resorption.
Osmotic and pH-related effects
Vancomycin solutions are acidic, and prolonged soaking may alter the local pH within the graft, creating a microenvironment that is hostile to cellular activity. Additionally, the high osmolarity of concentrated vancomycin solutions could induce osmotic stress in graft cells, further compromising viability. These physicochemical effects are rarely measured in clinical studies but may contribute to the observed resorption patterns.
While these mechanisms are biologically plausible, they remain speculative in the context of ACLR. No clinical study has directly measured vancomycin penetration, pH changes, or cellular viability within human grafts in vivo. Thus, the proposed mechanisms are based on extrapolation from in vitro and animal data rather than direct human evidence.
Who is affected: Patient populations and surgical contexts most at risk
Graft type and donor site
Most reports of early resorption have involved quadriceps tendon autografts soaked in vancomycin. The quadriceps tendon is relatively avascular compared to bone-patellar tendon-bone (BPTB) grafts, which may make it more susceptible to cytotoxic effects during the early healing phase. Some authors suggest that BPTB grafts, with their robust bone plug and higher vascularity, may be less vulnerable to vancomycin-induced resorption, though this has not been systematically evaluated.
Patient risk factors
Patients with systemic conditions that impair tissue healing—such as diabetes, rheumatoid arthritis, or chronic corticosteroid use—may be at higher risk of adverse effects from vancomycin soaking. These patients already have reduced cellular activity and delayed remodeling, which could compound the potential cytotoxic effects of vancomycin. Additionally, smokers and older adults may be more susceptible due to impaired vascular ingrowth and reduced progenitor cell recruitment.
Surgical technique and soaking protocol
The method and duration of vancomycin soaking vary widely across institutions. Some protocols recommend soaking for 10–15 minutes in a 5 mg/mL solution, while others use higher concentrations or longer exposure times. The lack of standardization makes it difficult to determine whether certain protocols are safer than others. Some surgeons report using shorter soak times or lower concentrations to mitigate potential harm, but these practices are not evidence-based and remain anecdotal.
How misinformation spreads: From anecdotal reports to premature adoption
The adoption of vancomycin-soaked grafts in ACLR exemplifies how medical innovations can spread through a feedback loop of anecdotal success, institutional enthusiasm, and premature standardization—before robust evidence is available. Early reports of reduced infection rates, often from high-volume surgeons or centers, were amplified through conference presentations, institutional protocols, and industry-sponsored educational materials. These narratives created a perception of safety and efficacy that outpaced the actual data.
Social media and professional networks further accelerated the dissemination of this practice. Surgeons shared personal experiences and case series on platforms such as OrthoBulletin, X (formerly Twitter), and closed professional forums, often without peer review or methodological critique. The result was a form of “digital confirmation bias,” where favorable outcomes were highlighted and adverse events were underreported or dismissed as isolated incidents.
This pattern mirrors historical precedents in orthopedic surgery, such as the rapid adoption of platelet-rich plasma (PRP) or synthetic bone substitutes, where initial enthusiasm was not matched by high-quality evidence. In each case, the gap between promise and proof created a cycle of overuse, followed by gradual reassessment as complications emerged.
Red flags and debunking checklist for clinicians and patients
- Absence of long-term data: If a surgical protocol relies on vancomycin-soaked grafts without published long-term outcomes (beyond 1–2 years), treat it as experimental. Demand institutional data or registry reports before assuming safety.
- Lack of standardized soaking protocols: Protocols that vary in concentration, duration, or technique across cases or surgeons introduce uncontrolled variables. Consistency is not evidence of safety.
- Overemphasis on infection reduction without mention of graft integrity: Be wary of presentations or papers that tout infection benefits while omitting data on graft healing, MRI follow-up, or functional outcomes.
- Reliance on anecdotal case reports or small series: A single surgeon’s experience with 10–20 cases is not sufficient to justify widespread adoption. Look for multi-center, peer-reviewed studies with control groups.
- Use of vancomycin in avascular grafts (e.g., quadriceps tendon): If your graft choice is already biologically disadvantaged, adding a potentially cytotoxic agent may compound the risk. Consider alternatives or modified protocols.
- No imaging follow-up beyond 6 months: Early resorption may not be clinically apparent until graft thinning is visible on MRI. Ensure that postoperative protocols include standardized imaging at 3–6 months and 1 year.
- Pressure to adopt due to “standard of care” claims: If a hospital or group claims that vancomycin-soaked grafts are now the “standard,” ask for the evidence base. Standards should be evidence-based, not consensus-driven without data.
Expert and institutional responses to emerging evidence
As reports of early graft resorption have surfaced, some institutions have begun to reassess their protocols. A small number of academic centers have paused routine vancomycin soaking for quadriceps tendon grafts while they review internal data and await further studies. Others have modified their protocols to use lower concentrations, shorter soak times, or alternative antibiotics such as tobramycin, which may have a more favorable safety profile.
Professional societies have not yet issued formal guidance on vancomycin-soaked grafts in ACLR. The American Academy of Orthopaedic Surgeons (AAOS) and the Arthroscopy Association of North America (AANA) have not released statements addressing this specific issue, though both organizations have emphasized the need for rigorous research on emerging techniques. This silence reflects the early stage of the evidence and the absence of consensus on how to interpret the current data.
Some surgeons have pushed back against the emerging concerns, arguing that the reported cases of resorption are isolated and that the infection prevention benefits outweigh any theoretical risks. They point to the lack of definitive evidence linking vancomycin to graft failure and caution against overreacting to anecdotal reports. This debate highlights the tension between evidence-based caution and clinical pragmatism in the face of evolving data.
Original analysis: What the pattern across sources suggests about current practice
Taken together, the available reports suggest a pattern that is all too familiar in orthopedic surgery: a well-intentioned intervention, initially framed as low-risk and high-benefit, later reveals subtle harms that were not anticipated in early studies. The rise of vancomycin-soaked grafts in ACLR appears to follow this trajectory. While the infection benefit is plausible and supported by retrospective data, the potential for graft resorption—particularly in avascular grafts and high-risk patients—has emerged as a plausible but unproven risk.
The most concerning aspect of this pattern is not the harm itself, but the speed with which the practice became institutionalized. The absence of randomized trials, standardized protocols, or long-term follow-up allowed vancomycin soaking to become a de facto standard in many centers before its safety could be rigorously evaluated. This is not a failure of individual surgeons, but a systemic issue: the medical community often privileges early adoption of promising techniques over delayed but more reliable evidence.
Moreover, the lack of transparency around adverse events—whether due to underreporting, publication bias, or simply the absence of systematic surveillance—has delayed the recognition of this signal. Only when multiple institutions independently observed similar patterns did the issue come to light. This suggests that future innovations in graft preparation or surgical technique should be accompanied by mandatory registries, standardized imaging protocols, and independent safety monitoring to detect subtle harms before they become widespread.
What to do now: Evidence-based recommendations for surgeons and patients
For surgeons
Surgeons should critically evaluate their use of vancomycin-soaked grafts in ACLR, particularly when using quadriceps tendon autografts. Consider the following steps:
- Pause routine use until more data are available: Given the plausible risk of early resorption and the lack of definitive evidence supporting safety, consider deferring routine vancomycin soaking until high-quality studies are published.
- Use alternative strategies for infection prevention: If infection risk is a concern, consider systemic antibiotic prophylaxis, meticulous surgical technique, and postoperative wound care rather than local antibiotic delivery.
- Implement standardized follow-up protocols: If vancomycin soaking is used, ensure that all patients undergo standardized MRI at 3–6 months and 1 year to monitor graft integrity. Report any cases of early resorption to institutional quality improvement programs and national registries.
- Document and share outcomes: Publish institutional experiences, even if negative, to contribute to the growing body of evidence. Transparency is essential to identify patterns that may not be apparent in small series.
For patients
Patients considering ACLR should discuss graft options and infection prevention strategies with their surgeon. Key questions include:
- Is vancomycin soaking routinely used in this practice, and what is the evidence supporting it?
- What is the expected infection rate with and without vancomycin soaking?
- What imaging follow-up is planned to monitor graft healing?
- Are there alternative strategies to reduce infection risk without potential harm to the graft?
Patients should be cautious of surgeons who present vancomycin soaking as a routine or risk-free practice without discussing the potential downsides. Shared decision-making should include a balanced discussion of both benefits and risks, even if the risks are not yet fully quantified.
FAQ
Is vancomycin soaking FDA-approved for ACL grafts?
No. Vancomycin is approved by the FDA for systemic use, but its use in graft soaking is an off-label application. There are no FDA-approved indications for soaking grafts in vancomycin or any other antibiotic prior to implantation.
Have any randomized controlled trials examined vancomycin-soaked grafts in ACLR?
No randomized controlled trials have been published to date that evaluate the efficacy or safety of vancomycin-soaked grafts in ACLR. All available data come from retrospective series, case reports, or institutional audits.
Can I still use vancomycin-soaked grafts if my surgeon recommends it?
If your surgeon recommends vancomycin-soaked grafts, ask about the rationale, the specific protocol (concentration, duration), and the planned follow-up imaging. If the surgeon cannot provide evidence of safety or a plan for monitoring graft integrity, consider seeking a second opinion.
Are there safer alternatives for infection prevention in ACLR?
Systemic antibiotic prophylaxis remains the gold standard for infection prevention in ACLR. Other strategies include meticulous surgical technique, minimizing tourniquet time, and postoperative wound care. Local antibiotic delivery should be considered experimental until more data are available.
What should I do if I experience persistent pain or instability after ACLR with a vancomycin-soaked graft?
Persistent pain, swelling, or instability after ACLR warrants prompt evaluation with your surgeon. Request an MRI to assess graft integrity and rule out early resorption or other complications. Report your experience to your surgeon and consider sharing de-identified details with institutional quality programs or national registries.